S. Hacein-Bey describes the history of gene therapy, the triumphs and failures of ex vivo gene transfer technology in hereditary diseases, the development of chimeric antigen receptor (CAR) T cell therapy for cancer, and the exciting opportunities that are emerging with new gene editing technologies such as CRISPR.
Summary
Introduction : Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress. Dominique BELLET et Jean-Paul TILLEMENT
New diagnostic and Therapeutic Technologies
Integration of individual genetic and kinetic characteristics for the pharmacological optimization of drug use. Pierre MARQUET
Toward precision medicine for age-related diseases: standardized geriatric assessment. Fati NOURHASHEMI
Genomic and precision medicine: setting problems and perspectives. Francis GALIBERT
Managing drug interactions: a clinical decision support system. Jacques TURGEON
Therapeutic targeting of Interleukin 17: An example of translational medicine. Pierre MIOSSEC
Realities and perspetives of precision medicine
Type 2 diabetes and hypercholesterolemia. André SCHEEN
Should we sequence each patient's tumour? Christophe LE TOURNEAU
Kidney transplantation: an emblematic example of precision medicine to solve an increasingly complex situation. Thierry HAUET
Gene, cellular and stem-cell therapies: perspectives and limits. Salima HACEIN-BEY
Precision Medicine: which applications, cost and targeted populations? Jean-Pierre MICHEL
Organizers
Authors
Organizers
Authors
Category
The patient
Publication type
Proceedings
Year
2017
Download the publication